Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

To be eligible for this study, you would need to have been diagnosed with diffuse large B-cell lymphoma (DLBCL) or certain related types of lymphoma that have transformed into DLBCL. Your cancer must have returned or continued to progress after your most recent treatment, and you should have tried between one and three previous treatments. It's also important that you are generally well enough to take part, as assessed by your doctor, and that you are not suitable for a stem cell transplant.

There are also some conditions that would mean you couldn't join the study. For example, if you have certain other specific types of lymphoma, or if your DLBCL was found to be 'primary refractory' (meaning it didn't respond at all to the very first treatment) or has certain genetic changes (like 'double- or triple-hit' DLBCL). You also shouldn't have had certain other cancer treatments or major surgery recently, or received live vaccines in the last month. The study also requires you to be willing to avoid getting pregnant or fathering a child during the study.

If you decide to take part in this study, you will receive the study medications, tafasitamab and lenalidomide. Your health will be carefully monitored throughout. This will involve regular visits to the clinic for check-ups, blood tests, and scans to see how the treatment is working and to monitor for any side effects. You might also be asked to provide tissue samples, like a biopsy of your tumour and bone marrow, both at the start and potentially during the study. The total duration of your participation in the study will depend on how you respond to the treatment and the study plan, but there will be ongoing follow-up to monitor your health. You will also have scheduled follow-up visits after stopping the study medication.